TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
UC-BCG-2503
Phase 2 small_molecule active
Quick answer
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN for Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication. is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active